Long-Term Outcomes of Treatment of Neovascular Age-Related Macular Degeneration Data from an Observational Study
Mark C Gillies, Anna Campain, Daniel Barthelmes, Judy M Simpson, Jennifer J Arnold, Robyn H Guymer, Ian L McAllister, Rohan W Essex, Nigel Morlet, Alex P Hunyor
OPHTHALMOLOGY | ELSEVIER SCIENCE INC | Published : 2015
PURPOSE: To analyze the long-term outcomes of eyes with neovascular age-related macular degeneration (AMD) starting treatment with vascular endothelial growth factor (VEGF) inhibitors at least 5 years earlier. DESIGN: Database observational study. PARTICIPANTS: Treatment-naïve eyes with neovascular AMD tracked by the Fight Retinal Blindness outcome registry that received at least 1 anti-VEGF injection. METHODS: Locally weighted scatterplot smoothing curves were used to display visual acuity (VA) results. MAIN OUTCOME MEASURES: Change in mean VA and number of injections and visits from baseline up to 7 years after initiating treatment. RESULTS: The mean follow-up time of all 1212 identified e..View full abstract
Awarded by National Health and Medical Research Council, Australia (NHRMC)
J.J.A. and R.H.G.: Personal fees and other - Novartis and other from Bayer, outside the submitted work.A.P.H.: Research grant - Novartis and Bayer.Supported by a grant from the Royal Australian New Zealand College of Ophthalmologists Eye Foundation (2007-2009) and a grant from the National Health and Medical Research Council, Australia (NHRMC 2010-2012; NHMRC grant no. ID 632663).M.C.G. is a Sydney Medical Foundation Fellow and is supported by an NHMRC practitioner fellowship. D.B. was supported by the Walter and Gertrud Siegenthaler Foundation Zurich, Switzerland, and the Swiss National Foundation. Funding was also provided by Novartis and Bayer. These supporting organizations had no role in the design or conduct of the research.